We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
-1.74%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.74B
AUM Growth
+$339M
(+14%)
Cap. Flow
+$26.5M
Cap. Flow
% of AUM
0.97%
Top 10 Holdings %
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$23.4M |
| 2 |
ExxonMobil
XOM
|
+$15.3M |
| 3 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$12.1M |
| 4 |
Merck
MRK
|
+$9.03M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
+$8.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tempest Therapeutics
TPST
|
+$53.9M |
| 2 |
AGN
Allergan plc
AGN
|
+$33.8M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$24.7M |
| 4 |
MBLY
Mobileye N.V.
MBLY
|
+$7.21M |
| 5 |
MannKind Corp
MNKD
|
+$5.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 88.95% |
| 2 | Healthcare | 8.73% |
| 3 | Energy | 1.53% |
| 4 | Technology | 0.21% |
| 5 | Industrials | 0.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
iShares S&P 100 ETF
OEF
$20.2B
| $224M | 8.17% |
18,137
-1,208
| -6% | -$112K |
|
2
CALL
Eli Lilly
LLY
$1.01T
| $223M | 8.12% |
26,671
+16,710
| +168% | +$1.27M |
|
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$803B
| $206M | 7.51% |
10,000
+2,559
| +34% | +$538K |
|
4
CALL
Biogen
BIIB
$32.1B
| $176M | 6.4% |
4,345
+1,243
| +40% | +$499K |
|
5
CALL
Gilead Sciences
GILD
$182B
| $151M | 5.5% |
12,877
+2,910
| +29% | +$318K |
|
|
6
CALL
Merck
MRK
$357B
| $56.9M | 2.08% |
10,480
-7,533
| -42% | -$422K |
|
7
CALL
AbbVie
ABBV
$463B
| $53.9M | 1.96% |
8,015
-2,292
| -22% | -$150K |
|
8
CALL
BioMarin Pharmaceuticals
BMRN
$12.9B
| $51.9M | 1.89% |
3,796
+1,635
| +76% | +$203K |
|
9
CALL
Alnylam Pharmaceuticals
ALNY
$33.5B
| $49.8M | 1.82% |
4,157
+908
| +28% | +$109K |
|
10
PUT
Regeneron Pharmaceuticals
REGN
$81.7B
| $46.3M | 1.69% |
907
+328
| +57% | +$160K |
|
|
11
PUT
Biogen
BIIB
$32.1B
| $44.8M | 1.64% |
1,110
+596
| +116% | +$239K |
|
12
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.5B
| $44.6M | 1.63% |
+5,998
| New | +$445K |
|
13
PUT
Tenet Healthcare
THC
$21.3B
| $35.6M | 1.3% |
6,148
+396
| +7% | +$20.2K |
|
|
14
PUT
Gilead Sciences
GILD
$182B
| $34.4M | 1.25% |
2,935
+1,103
| +60% | +$121K |
|
15
PUT
Teva Pharmaceuticals
TEVA
$45.1B
| $30.8M | 1.12% |
5,210
+3,695
| +244% | +$228K |
|
|
16
PUT
Merck
MRK
$357B
| $29.8M | 1.09% |
5,485
-760
| -12% | -$42.6K |
|
|
17
iShares 20+ Year Treasury Bond ETF
TLT
$46.6B
| $28.9M | 1.05% |
246,000
+190,680
| +345% | +$23.4M |
|
|
GWPH
18
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $25.3M | 0.92% |
2,062
+139
| +7% | +$15.8K |
|
|
19
PUT
AbbVie
ABBV
$463B
| $24.9M | 0.91% |
3,704
+1,820
| +97% | +$119K |
|
|
20
PUT
ExxonMobil
XOM
$679B
| $24.4M | 0.89% |
+2,933
| New | +$252K |
|
|
BLUE
21
CALL
DELISTED
bluebird bio
BLUE
| $24.1M | 0.88% |
110
-121
| -52% | -$246K |
|
|
22
PUT
BioMarin Pharmaceuticals
BMRN
$12.9B
| $22.6M | 0.82% |
1,652
+1,143
| +225% | +$142K |
|
23
PUT
Viatris
VTRS
$19.1B
| $22.1M | 0.81% |
3,256
+256
| +9% | +$18.1K |
|
|
MBLY
24
PUT
DELISTED
Mobileye N.V.
MBLY
| $21.9M | 0.8% |
4,122
-1,514
| -27% | -$71.7K |
|
25
CALL
Sarepta Therapeutics
SRPT
$2.21B
| $20.5M | 0.75% |
6,723
-544
| -7% | -$11.1K |
|
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q2 2015 Portfolio in Review
As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Sabby Management's Q2 2015 filing shows 120 new, 93 increased, 80 reduced and 88 closed positions. Its largest new stake was ExxonMobil: 178,310 shares worth $14.8M. The largest sale was Tempest Therapeutics, an estimated $53.9M.
By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, up from 89% a quarter earlier, followed by Healthcare and Energy.
- Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
- Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
- Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
- Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
- Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
- Sabby Management opened 120 new positions and closed 88 in Q2 2015.
- Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.
Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.